作者
Robert Flisiak, Mariusz Łucejko, Włodzimierz Mazur, Ewa Janczewska, Hanna Berak, Krzysztof Tomasiewicz, Iwona Mozer-Lisewska, Dorota Kozielewicz, Andrzej Gietka, Katarzyna Sikorska, Marta Wawrzynowicz-Syczewska, Krzysztof Nowak, Dorota Zarębska-Michaluk, Joanna Musialik, Krzysztof Simon, Aleksander Garlicki, Robert Pleśniak, Barbara Baka-Ćwierz, Iwona Olszok, Krystyna Augustyniak, Wojciech Stolarz, Jolanta Białkowska, Anna Badurek, Anna Piekarska
发表日期
2017/9/1
期刊
Advances in medical sciences
卷号
62
期号
2
页码范围
387-392
出版商
Elsevier
简介
Background
To evaluate the effectiveness and safety of ledipasvir/sofosbuvir (LDV/SOF) ± ribavirin (RBV) regimen in a real-world setting.
Methods
Patients received a fixed-dose combination tablet containing LDV and SOF with or without RBV, for 8, 12 or 24 weeks. Patients were assessed at baseline, end of treatment, and 12 weeks after the end of treatment. The primary effectiveness endpoint was sustained virologic response 12 weeks after the end of treatment (SVR12).
Results
Of the 86 patients, aged 20–80 years, 82.6% were HCV genotype 1b-infected and 50.0% were cirrhotic. More than half (52.3%) had previously followed pegylated interferon-containing (PEG-IFN) treatment regimens, and 38.5% were null-responders. SVR12 was achieved by 94.2% of patients. All non-responders were cirrhotic: two demonstrated virologic breakthrough and the remaining three relapsed. All patients treated with an 8-week …
学术搜索中的文章
R Flisiak, M Łucejko, W Mazur, E Janczewska, H Berak… - Advances in medical sciences, 2017